Outcomes for Patients with Late-Stage Mutant-IDH2 (m IDH2) Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Treated with Enasidenib Vs Other Lower-Intensity Therapies in the Randomized, Phase 3 IDHentify Trial
DiNardo CD., Montesinos P., Schuh AC., Papayannidis C., Vyas P., Wei AH., Zeidan AM., Bluemmert I., Yu X., Hasan M., Martin-Regueira P., de Botton S.